Table 1.

Effects of Combining JAK Inhibitor (AZD1480) with SRC Inhibitor (Dasatinib and Saracatinib), AKT Inhibitor (MK2204), and MEK Inhibitor (AZD6244) on the Viability of Ovarian Cancer Cells

	Inhibitors Combined with JAKi	Fold Reduction		CI
		IC50	IC90	ED50	ED75	ED90
SKOV3	SRCi (Dasatinib)	25.32	31.81	0.53	0.08	0.03
	SRCi (Saracatinib)	43.17	29.62	0.27	0.03	0.03
	AKTi (MK2206)	4.24	1.31	0.48	0.72	1.67
	mTORi (RAD001)	6.29	1.86	0.19	0.29	0.54
	MEKi (AZD6244)	0.50	0.85	2.21	2.33	2.54
OVCAR8	SRCi (Dasatinib)	2.26	2.53	0.62	0.59	0.56
	SRCi (Saracatinib)	2.54	4.52	0.59	0.37	0.25
	AKTi (MK2206)	2.07	1.24	0.72	0.90	1.13
	MEKi (AZD6244)	1.77	1.08	0.57	0.72	0.92
MDAH2774	SRCi (Dasatinib)	8.41	1.24	0.27	0.47	0.80
	SRCi (Saracatinib)	4.09	5.55	0.29	0.34	0.39
	AKTi (MK2206)	2.18	2.39	0.63	0.47	0.42
	MEKi (AZD6244)	9.33	3.31	0.21	0.18	0.30